The emerging role of NRAS mutations in colorectal cancer patients selected for anti-EGFR therapies

Reviews on Recent Clinical Trials

Volumn 9, Issue 1, 2014, Pages 8-12

  Meriggi, Fausto ^a   Vermi, William ^b,c   Bertocchi, Paola ^a   Zaniboni, Alberto ^a  

^a Fondazione Poliambulanza   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti egfr; Cetuximab; Colorectal cancer; Epidermal growth factor receptor; Kras; Monoclonal antibodies; Mutations; Nras; Panitumumab

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; VASCULOTROPIN INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN;

CANCER PATIENT; CANCER SURVIVAL; CHROMOSOME 1; COLORECTAL CANCER; EXON; GENE MUTATION; HUMAN; INFLAMMATION; MONITORING; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; GENETICS; MUTATION;

COLORECTAL NEOPLASMS; GTP PHOSPHOHYDROLASES; HUMANS; MEMBRANE PROTEINS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84901750791     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/1568026614666140423121525     Document Type: Review

References (45)

1. Jernal A, Siegel R, Xu J, et al. Cancer Statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. AIOM-AIRTUM: i numeri del cancro in Italia 2013. Intermedia Editore, 2013.
3. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006; 12: 5268-5272.
4. Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, flourouracil and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-9.
5. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22: 1535-46.
6. Tveit K, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. Journal of Clinical Oncology 2012; 30: 1755-1762.
7. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27: 672-680.
8. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705
9. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-14.
10. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-72.
11. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-6.
12. De Roock W, Claes B, Bernasconi D, De Schutter J, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62.
13. Wang Y, Velho S, Vakiani E, et al. Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression. Cancer Discov 2013; 3: 294-307.
14. Haigis KM, Kendall KR, Wang Y, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008; 40: 600-608.
15. Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011; 50: 307-12.
16. Peeters M, Oliner KS, Parker A, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 2013; 19: 1902-1912.
17. Douillard J-Y, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034.
18. Stintzing S, Jung A, Rossius L, et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Ann Oncol 2013; 24: (suppl;LBA E17-7073), 17th ECCO-38th ESMO-32nd ESTRO, Amsterdam, 28-30/9/2013.
19. Ciardiello F, Normanno N, Maiello E, et al. Molecular profiling of the CAPRI GOIM trial in KRAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pts): Cetuximab + FOLFIRI followed by FOLFOX4 + cetuximab. Ann Oncol 2013; 24: (suppl;LBA 31), 17th ECCO-38th ESMO-32nd ESTRO, Amsterdam, 28-30/9/2013.
20. Karthaus M, Schwartzberg L, Rivera F, et al. Updated overall survival (OS) analysis of novel predictive KRAS/NRAS mutations beyond KRAS exon 2 in PEAK: A first-line phase 2 study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC). Ann Oncol 2013; 24: (suppl;Abstr 2262), 17th ECCO-38th ESMO-32nd ESTRO, Amsterdam, 28-30/9/2013.
21. Schirripa M, Loupakis F, Cremolini C, et al. Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts). J Clin Oncol 2013; 31 (suppl; abstr 3613).
22. Di Bartolomeo M, Pietrantonio F, Perrone F, et al. Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. Target Oncol 2013 Jul 3. [Epub ahead of print]
23. Fornaro L, Lonardi S, Masi G, et al. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol 2013; 24: 2062-2067.
24. Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 2012; 30: 2956-62.
25. Smith CG, Fisher D, Claes B, Maughan TS, Idziaszczyk S, Peuteman G, Harris R, James MD, Meade A, Jasani B, Adams RA, Kenny S, Kaplan R, Lambrechts D, Cheadle JP. Somatic profiling of the epidermal growth factor receptor pathway in tumours from patients with advanced colorectal cancer, treated with chemotherapy +/-cetuximab. Clin Cancer Res 2013; 19: 4104-13.
26. Pentheroudakis G, Kotoula V, De Roock W, et al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer 2013; 13: 49.
27. Troiani T, Zappavigna S, Martinelli E, et al. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Expert Opin Biol Ther 2013; 13: 241-255.
28. Domingo E, Ramamoorthy R, Oukrif D, et al. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. J Pathol 2013; 229: 441-8.
29. Custodio A, Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Crit Rev Oncol Hematol 2013; 85: 45-81.
30. De Mattos-Arruda L, Dienstmann R, Tabernero J. Development of molecular biomarkers in individualized treatment of colorectal cancer. Clin Colorectal Cancer 2011; 10: 279-89.
31. Balschun K, Haag J, Wenke AK, von Schönfels W, Schwarz NT, Röcken C. KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications. J Mol Diagn. 2011; 13: 436-45.
32. Dienstmann R, Vilar E, Tabernero J. Molecular predictors of response to chemotherapy in colorectal cancer. Cancer J. 2011; 17: 114-26.
33. Irahara N, Baba Y, Nosho K, et al. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol. 2010; 19: 157-63.
34. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can testing of tumor issue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Genetics in Medicine 2013; 15: 517-527.
35. Mouradov D, Domingo E, Gibbs P, et al. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am J Gastroenterol. 2013 Nov; 108: 1785-93.
36. Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012; 18: 6531-41.
37. Fumagalli D, Gavin PG, Taniyama Y, et al. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer. 2010; 10:101.
38. Irahara N, Baba Y, Nosho K, et al. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 2010; 19: 157-63.
39. Catalogue of somatic mutations in cancer v67. http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/
40. Cottrell CE, Al-Kateb H, Bredemeyer AJ, et al. Validation of a Next-Generation Sequencing Assay for Clinical Molecular Oncology. J Mol Diagn. 2013; 6. pii: S1525-1578(13)00219-5.
41. Hadd AG, Houghton J, Choudhary A, et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn. 2013; 15: 234-47.
42. McCourt CM, McArt DG, Mills K, et al. Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PLoS One. 2013; 8: e69604.
43. Singh RR, Patel KP, Routbort MJ, et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn. 2013; 15: 607-22.
44. Diaz LA Jr, Williams RT, Wu J, Kinde I, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012; 486: 537-40.
45. Centers for Disease Control and Prevention, Office of Public Health Genomics. Can molecular testing indicate optimal treatment in metastatic colorectal cancer? Medscape. Jul 01, 2013.